N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)- 4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor

Molecular Pharmacology

Volumn 62, Issue 6, 2002, Pages 1274-1287

  Hurst, Dow P ^a   Lynch, Diane L ^a   Barnett Norris, Judy ^a   Hyatt, Stephen M ^b   Seltzman, Herbert H ^b   Zhong, Miao ^c   Song, Zhao Hui ^c   Nie, Jingjiang ^d   Lewis, Deborah ^d   Reggio, Patricia H ^a  

^a KENNESAW STATE UNIVERSITY   (United States)

^b RTI INTERNATIONAL   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLOROPHENYL) 3 (2 CYCLOHEXYLETHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOLE; BARIUM ION; CALCIUM CHANNEL; CALCIUM ION; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; COMPLEMENTARY DNA; COMPLEMENTARY RNA; G PROTEIN COUPLED RECEPTOR; RIMONABANT; TRITIUM; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EMBRYO; ENERGY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HYDROGEN BOND; LIGAND BINDING; MOLECULAR MODEL; NERVE CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SUPERIOR CERVICAL GANGLION; THERMODYNAMICS;

BINDING SITES; CALCIUM; CELLS, CULTURED; ELECTROPHYSIOLOGY; HUMANS; LIGANDS; LYSINE; MODELS, MOLECULAR; NEURONS; PIPERIDINES; PROTEIN CONFORMATION; PYRAZOLES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TRANSFECTION;

EID: 0036892304     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.62.6.1274     Document Type: Article

References (40)

1. 2 adrenergic receptors control the equilibrium between active and inactive receptor states. Mol Pharmacol 57:198-210.
2. 2-adrenergic receptor involves disruption of an ionic lock between the intracellular ends of transmembrane segment 3 and 6. J Biol Chem 276:29171-29177.
3. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three dimensional models and computational probing of structure function relations in G protein-coupled receptors, in Methods in Neuroscience (Conn PM and Sealfon SC eds) Vol 25, pp 366-428, Academic Press, San Diego.
4. Barnett-Norris J, Hurst DP, Buehner K, Ballesteros JA, Guarnieri F, and Reggio PH (2002a) Agonist alkyl tail interaction with cannabinoid CB1 receptor V6:43/I6.46 groove induces a Helix 6 active conformation. Int J Quantum Chem 88:76-86.
5. Barnett-Norris J, Reggio PH, Hurst D, and Guarnieri F(2002b) Global positioning of TMH 3 extracellular end in CB1 receptor is controlled by interplay of two, small polar residues. Biophys J 82:533a.
6. Barth F, Casellas P, Congy C, Martinez S, Rinaldi M, Gilles A (1995) inventors, Sanofi, assignee. Preparation of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)- 4-methylpyrazole-3-carboxamide as a cannabinoid receptor antagonist. EP patent 656 354 Al. 1995 June 7.
7. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, et al. (1997) A selective inverse agonist for the central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. J Biol Chem 272:22330-22339.
8. Bramblett RD, Panu AM, Ballesteros JA, and Reggio PH (1995) Construction of a 3D model of the cannabinoid CB1 receptor: Determination of helix ends and helix orientation. Life Sci 56:1971-1982.
9. Burley S and Petsko G (1985) Aromatic-aromatic interaction: A mechanism of protein structure stabilization. Science (Wash DC) 229:23-28.
10. Chen C and Okayama H (1987) High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7:2745-2752.
11. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
12. Chin C, Lucas-Lenard J, Abadjii V, and Kendall DA (1998) Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. J Neurochem 70:366-373.
13. Costa T, Ogino Y, Munson PJ, Onaran HO, and Rodbard D (1992) Drug effects at guanine nucleotide regulatory binding protein linked receptors: Thermodynamic interpretation of negative antagonism of receptor activation in the absence of ligand. Mol Pharmacol 41:549-560.
14. DeBlasi A, O'Reilly K, and Motulsky HJ (1989) Calculating receptor number from binding experiments using same compound as radioligand and competitor. Trends Pharmacol Sci 10:227-229.
15. Faiman GA and Horovitz A (1996) On the choice of reference mutant states in the application of the double-mutant cycle method. Protein Eng 9:315-316.
16. Farrens DL, Altenbach C, Yang K, Hubbell WL, and Khorana HG (1996) Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science (Wash DC) 274:768-770.
17. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL, and Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Phar. Macol 48:443-450.
18. Gerard CM, Mollereau C, Vassart G, and Parmentier M (1991) Molecular cloning of a human brain cannabinoid receptor which is also expressed in testis. Biochem J 279:129-134.
19. Hunter C, Singh J, and Thornton J (1991) π-π Interactions: The geometry and energetics of phenylalanine-phenylalanine interactions in proteins. J Mol Biol 218:837-846.
20. 2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J Biol Chem 272:18546-18549.
21. 2 adrenergic receptor mapped by site-selective fluorescent labeling. J Biol Chem 276:9279-9290.
22. Leff P (1995) The two-state model of receptor activation. Trends Pharmacol Sci 16:89-97.
23. Lin SW and Sakmar TP (1996) Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. Biochemistry 35:11149-11159.
24. McAllister SD, Tao Q, Barnett-Norris J, Buehner K, Hurst DP, Guarnieri F, Reggio PH, Nowell Harmon KW, Cabral GA, and Abood ME (2002) A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition. Biochem Pharmacol 7260:1-16.
25. McLoughlin DJ and Strange PG (2000) Mechanism of agonism and inverse agonism at serotonin 5-HT 1A receptors. J Neurochem 74:347-357.
26. Mackie K, Lai Y, Westenbroek R, and Mitchell R (1995) Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptors. J Neurosci 15:6552-6561.
27. Meschler JP, Kraichely DM, Wilken GH, and Howlett AC (2000) Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)- 4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxylic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor. Biochem Pharmacol 60:1315-1323.
28. Mortimer RG (1981) Mathematics for Physical Chemistry. Macmillan Publishing Co., New York.
29. Munro S, Thomas KL, and Abu-Sharr M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature (Lond) 365:61-65.
30. Musafia B, Buchner V, and Arad D (1995) Complex salt bridges in proteins: Statistical analysis of structure and function. J Mol Biol 254:761-770.
31. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima HBA, Fox BA, LeTron I, Teller DC, Okada T, Stenkamp RE, et al. (2000) Crystal structure of rhodopsin: A G-protein-coupled receptor. Science (Wash DC) 289:739-745.
32. 2+ channels in a neuronal expression system. Mol Pharmacol 49:707-714.
33. 2+ currents by reversal of tonic CB1 receptor activity. Mol Pharmacol 54:1064-1072.
34. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
35. 2-adrenergic receptor. Mol Pharmacol 45:390-394.
36. Shire D, Calandra B, Bouaboula M, Barth F, Rinaldi-Carmona M, Casellas P, and Ferrara P (1999) Cannabinoid receptor interactions with the antagonists SR141716A and SR144528. Life Sci 65:627-635.
37. Sim-Selley LJ, Brunk LK, and Selley DE (2001) Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur J Pharmacol 414:135-143.
38. Song ZH and Bonner TI (1996) A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists, but not WIN-55,212. Mol Pharmacol 49:891-896.
39. Vásquez C and Lewis DL (1999) The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J Neurosci 19:9271-9280.
40. Visiers I, Ballesteros JA, and Weinstein H (2002) Three-dimensional representations of G protein-coupled receptor structures and mechanisms. Methods Enzymol 343: 329-371.